“…Antimyelin component antibodies generated under pathological conditions might have either adverse or beneficial effects (van der Veen et al, 1986(van der Veen et al, , 1989Endoh et al, 1986;Sadler et al, 1991;Potter and Stephens, 1994;Genain et al, 1995;Laman et al, 2001;Morris-Downes et al, 2002;Mitsunaga et al, 2002;Schwab, 2004). Moreover, potential pathogenetic roles for antimyelin antibodies, including anti-PLP antibodies, have been suggested in MS (Sun et al, 1991;Warren et al, 1994;Sellebjerg et al, 1995Sellebjerg et al, , 2000Archelos et al, 2000;Carvalho et al, 2003;Berger et al, 2003;Qin et al, 2003;Kanter et al, 2005;Zhang et al, 2005a).…”